ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2021 Results

ICON Reports Fourth Quarter and Full Year 2021 Results

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 2022 Citi Healthcare Conference

ICON plc to Present at the 2022 Citi Healthcare Conference

DUBLIN--(BUSINESS WIRE)--ICON Issues Financial Guidance for Full Year 2022

ICON Issues Financial Guidance for Full Year 2022

DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference

ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference

DUBLIN--(BUSINESS WIRE)--ICON was named “Best CRO” at the Scrip Awards by Pharma Intelligence and to the World's Best Employer list by Forbes, among many awards won in 2021.

ICON Named Best Contract Research Organisation in Latest String of Industry Awards

DUBLIN--(BUSINESS WIRE)--ICON Releases Environmental, Social and Governance Report

ICON Releases Environmental, Social and Governance Report

DUBLIN, Ireland--(BUSINESS WIRE)-- #ICON--ICON announces the expansion of the Accellacare Site Network, with six new clinical research sites in Germany, Poland, Spain and the U.S.

ICON Announces the Expansion of its Accellacare Site Network

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q3 2021 Results - Earnings Call Transcript

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference

ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference

Icon PLC (ICLR) delivered earnings and revenue surprises of 4.94% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Q3 Earnings and Revenues Beat Estimates

DUBLIN--(BUSINESS WIRE)--ICON Reports Third Quarter 2021 Results

ICON Reports Third Quarter 2021 Results

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Icon PLC (ICLR) to Report Q3 Results: Wall Street Expects Earnings Growth

DUBLIN, Ireland--(BUSINESS WIRE)-- #CRO--Dublin-based ICON plc has been awarded €4 million in R&D support to further enhance its data solutions and decentralised clinical trial technology.

Tánaiste announces multi-million Euro R&D support of ICON to accelerate decentralised clinical trial technology

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference

ICON plc to Present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference

ICON Public Limited Company is a leading clinical research organization, aiding researchers and companies across the entire industry in performing their work. The healthcare industry is extremely strong at the moment and set to see favorable tailwinds over the next few years.

ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research

Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Icon PLC (ICLR) Soars to 52-Week High, Time to Cash Out?

Icon PLC (ICLR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Icon PLC (ICLR) Stock

AutoNation

Dollar General

Devon Energy

ICLR, DG, AN, and DVN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 26, 2021

Top Ranked Growth Stocks to Buy for July 26th

ICON Public Limited Company (ICLR) CEO Steve Cutler on Q2 2021 Results - Earnings Call Transcript

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.95% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates

DUBLIN--(BUSINESS WIRE)--ICON Reports Second Quarter 2021 Results

ICON Reports Second Quarter 2021 Results

Icon (NASDAQ:ICLR) releases its next round of earnings this Thursday, July 22. Here is Benzinga's essential guide to Icon's Q2 earnings report.

Earnings Preview: Icon

Icon PLC (ICLR) could produce exceptional returns because of its solid growth attributes.

Is Icon PLC (ICLR) a Solid Growth Stock? 3 Reasons to Think " Yes "

Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Icon PLC (ICLR) Soars 4.4%: Is Further Upside Left in the Stock?

DUBLIN--(BUSINESS WIRE)--ICON acquisition creates world-leading healthcare intelligence and clinical research organisation

News for ICON Stock (ICLR)